Biotech Funding Terms Glossary: VC, IPO, and M&A Definitions (2026)

Pre-money valuation

Company value before new money comes in. Used to calculate price per share and dilution.

Post-money valuation

Pre-money + new money invested. If you raise $50M on a $200M pre, post is $250M.

Dilution

The percentage ownership existing shareholders give up when new shares are issued. It's not "bad" — it's the cost of capital.

Option pool / ESOP

Shares reserved for employees. Investors often require a "pool top-up" at a new round, which increases dilution to existing holders.

Price per share

Implied share price set by the financing. Determines how many new shares are issued for the amount raised.

Fully diluted (FD) shares

Total shares assuming all options, warrants, and convertibles are exercised or converted. "FD % ownership" is what most investors care about.

Runway

How long the company can operate at current burn rate before running out of cash — often stated in months.

Burn rate

Net cash spent per month or quarter. In biotech, clinical trials and manufacturing scale-up usually drive burn.

Seed

Early capital to form the company and generate initial data — target validation, lead discovery, IND planning.

Series A / B / C

Staged VC rounds. In biotech: A often funds IND + Phase 1; B funds Phase 1/2; C funds Phase 2/3 or multiple programs. These are general rules, not hard conventions.

Extension / "A-1", "B-2", etc.

An add-on to an existing round, sometimes at the same price, sometimes at a step-up.

Bridge round

Short-term financing meant to reach a specific milestone (e.g., data readout) or an IPO/M&A process.

Crossover round

Private round that includes public-market investors, typically ahead of an IPO. Signals IPO intent and helps anchor valuation.

Venture debt

Debt financing for VC-backed companies, often with warrants. Extends runway but adds repayment obligations.

See these round types in practice in examples of recent biotech funding rounds.

Preferred vs common stock

Preferred (investors) usually carries extra rights — liquidation preference, anti-dilution, voting. Common (founders, employees) is junior in payouts.

Liquidation preference (liq pref)

Investor gets paid back first — often 1x invested capital — before common receives any proceeds in an exit.

Participating preferred

Investor gets their preference and then shares in remaining proceeds. Less common in top-tier biotech VC but can appear in tougher markets.

Anti-dilution (broad-based weighted average)

Protects investors if a future round prices below the current round (a "down round"). Weighted-average is the more standard, less punitive form.

Pay-to-play

Requires existing investors to participate in a financing to keep certain rights or avoid penalties. Usually appears in stressed situations.

Pro-rata rights

Right to maintain ownership percentage by investing in future rounds. Valuable when a company breaks out and rounds are oversubscribed.

Tranched financing

Investment released in stages based on milestones — IND filing, Phase 1 data, etc. Lowers risk for investors; can constrain company flexibility.

Syndicate

Group of investors in a round. The lead investor sets terms; followers join on the same terms.

Board seat / observer

A board seat is voting governance; an observer attends but typically does not vote. Usually tied to ownership threshold or round leadership.

For which investors join the most syndicates, see the biotech investor participation league table — a dated snapshot (1 Jan – 17 May 2026), not a list of lead investors for every round.

"Up to" / total potential value

Headline value including all milestones. Actual cash paid depends on clinical, regulatory, and commercial success.

Upfront

Guaranteed payment at signing or close. The most useful number for comparing deals — everything else is contingent.

Milestones

Contingent payments tied to specific development, regulatory, or commercial outcomes.

Royalties

Percentage of net sales paid to a licensor on an ongoing basis. Common in licensing and asset deals.

Equity value vs enterprise value (EV)

Equity value is the value paid for shares. EV adjusts for net debt and sometimes other items. Press releases typically cite equity value.

Compare how these terms are disclosed in licensing deals with upfronts, milestones and royalties.

IPO

Initial public offering. Biotech IPOs often price on catalysts and crossover support, and may include insider participation at the offer price.

Follow-on offering

A public company selling new shares after IPO — often after a catalyst or when the equity market window is open.

ATM (at-the-market)

Program to sell shares gradually into the open market. Useful for opportunistic fundraising without a single large transaction.

PIPE

Private investment in public equity. Often used when the public market window is weak; can be dilutive and may include warrants or discounts.

Warrants

Option-like securities that let holders buy shares later at a set price. Common in PIPEs, venture debt, and stressed financings.

The IPO tracker covers IPOs only, not every follow-on, ATM or PIPE. See recent biotech IPOs and their pricing.

Tender offer

The acquirer offers to buy shares directly from shareholders at a set price. The standard mechanism in public company takeouts.

CVR (contingent value right)

A right to receive additional payout if specified milestones are met post-acquisition. Used to bridge valuation gaps between buyer and seller.

Earnout

Additional payment based on performance targets post-close. Less common in pure biotech M&A than in services or software deals.

Break fee (termination fee)

Fee paid if the deal is terminated under specific conditions — e.g., a superior proposal. The size and direction signal deal certainty dynamics.

See how acquisitions are structured in recent biotech acquisitions and deal structures.